Overview

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Thymoglobulin
Vidarabine